))
DME/Retina Edition: Top Headlines for Week of August 5, 2024
Manage episode 433131307 series 3560281
コンテンツは Healio によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Healio またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
References:
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.
Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
115 つのエピソード
シェア
